Latest Molecular Diagnostics News

Pacific Edge reported a $35.8 million loss in FY26 amid a 47% revenue drop following Medicare coverage loss, but a draft Medicare policy and $36.1 million capital raise set the stage for recovery.

Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.

Genetic Signatures has locked in a 10-year supply deal with Denmark’s Hvidovre Hospital for its EasyScreen™ Pan-Enteric assay, marking a significant step in its European expansion. The agreement covers 28,000 tests in the first year with growth expected, leveraging the company’s proprietary 3base® technology to streamline complex gastrointestinal pathogen detection.

Genetic Signatures is undertaking a major organisational restructure to cut costs by $5 million and sharpen its commercial focus, aiming to accelerate growth in its diagnostic product offerings.

Genetic Signatures has appointed Anne Lockwood as interim Managing Director, bringing extensive financial expertise to guide the company through a critical transition period.

Genetic Signatures has appointed Maria Halasz as its new CEO, bringing over two decades of leadership in life sciences and capital markets to steer the company’s global expansion.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.

Genetic Signatures announces the upcoming departure of CEO Allison Rossiter, initiating a leadership transition as the company intensifies its focus on US market expansion.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Genetic Signatures Limited unveiled a year of strategic transformation and robust financial growth at its 2025 AGM, highlighting leadership renewal and a sharpened commercial focus. The company’s FY25 revenue jumped 66%, driven by strong product demand and expanded market presence.

Genetic Signatures Ltd reports a robust start to FY2026 with a 20% quarterly sales increase, driven by new US contracts and strong growth in EMEA and Australia. The company also bolsters its leadership with a new CTO appointment.

Genetic Signatures reported a 63% revenue increase to $15.9 million in FY25, alongside a 28% reduction in underlying losses and a strategic shift in its automated diagnostics platform development.